List of Xatmep drug patents

Xatmep is owned by Azurity.

Xatmep contains Methotrexate Sodium.

Xatmep has a total of 5 drug patents out of which 0 drug patents have expired.

Xatmep was authorised for market use on 25 April, 2017.

Xatmep is available in solution;oral dosage forms.

Xatmep can be used as a method for treating acute lymphoblastic leukemia; treatment of juvenile rheumatoid arthritis, treatment of juvenile rheumatoid arthritis; a method for treating acute lymphoblastic leukemia.

The generics of Xatmep are possible to be released after 02 January, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231927 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

US11116724 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

US10610485 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

US9855215 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

US9259427 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 25, 2024

Drugs and Companies using METHOTREXATE SODIUM ingredient

Market Authorisation Date: 25 April, 2017

Treatment: A method for treating acute lymphoblastic leukemia; Treatment of juvenile rheumatoid arthritis

Dosage: SOLUTION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic